INDUCING REMISSION IN MELANOMA PATIENTS WITH CHECKPOINT INHIBITOR THERAPY USING FECAL MICROBIOTA TRANSPLANTATION.
Latest Information Update: 08 Sep 2023
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms IRMI-FMT
- 29 Aug 2023 This trial has been Discontinued in Austria, according to European Clinical Trials Database record.
- 16 Jun 2021 New trial record